UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
UNITY Biotechnology (NASDAQ: UBX) has announced an in-person and virtual Ophthalmology Day event for investors and analysts on October 15, 2024, in New York. The event will feature presentations from ophthalmology key opinion leaders and company management, focusing on UNITY's ongoing Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) against aflibercept in diabetic macular edema (DME).
The agenda includes discussions on the senolytic therapeutic hypothesis, UBX1325 clinical development plan, and a retina expert roundtable. Twenty-four-week safety and efficacy data are expected in Q1 2025, with 36-week data in Q2 2025. The event will address the evolving therapeutic landscape and UBX1325's potential to meet unmet needs in DME. Virtual attendees can access the webcast through UNITY's website, with replays available for 90 days.
UNITY Biotechnology (NASDAQ: UBX) ha annunciato un evento in presenza e virtuale dedicato alla Giornata dell'Oftalmologia per investitori e analisti il 15 ottobre 2024 a New York. L'evento presenterà interventi da parte di leader di opinione nell'oftalmologia e della direzione aziendale, incentrandosi sullo studio ASPIRE di Fase 2b di UNITY che valuta foselutoclax (UBX1325) rispetto all'aflibercept nel edema maculare diabetico (DME).
L'agenda include discussioni sulla ipotesi terapeutica senolitica, il piano di sviluppo clinico di UBX1325, e un tavolo rotondo di esperti in retina. I dati di sicurezza ed efficacia dopo ventiquattro settimane sono attesi nel primo trimestre del 2025, con i dati a trentasei settimane nel secondo trimestre del 2025. L'evento affronterà il panorama terapeutico in evoluzione e il potenziale di UBX1325 nel soddisfare esigenze insoddisfatte nel DME. I partecipanti virtuali possono accedere al webcast attraverso il sito web di UNITY, con le registrazioni disponibili per 90 giorni.
UNITY Biotechnology (NASDAQ: UBX) ha anunciado un evento presencial y virtual de Día de la Oftalmología para inversores y analistas el 15 de octubre de 2024 en Nueva York. El evento contará con presentaciones de líderes de opinión clave en oftalmología y de la dirección de la empresa, centrándose en el estudio ASPIRE de Fase 2b de UNITY que evalúa foselutoclax (UBX1325) frente al aflibercept en edema macular diabético (DME).
La agenda incluye discusiones sobre la hipótesis terapéutica senolítica, el plan de desarrollo clínico de UBX1325, y una mesa redonda de expertos en retina. Se esperan datos de seguridad y eficacia a las veinticuatro semanas en el primer trimestre de 2025, con datos a las treinta y seis semanas en el segundo trimestre de 2025. El evento abordará el panorama terapéutico en evolución y el potencial de UBX1325 para satisfacer necesidades no cubiertas en DME. Los asistentes virtuales pueden acceder a la transmisión web a través del sitio web de UNITY, con repeticiones disponibles por 90 días.
UNITY Biotechnology (NASDAQ: UBX)는 투자자 및 분석가를 위한 대면 및 가상 안과의 날 행사를 2024년 10월 15일 뉴욕에서 개최한다고 발표했습니다. 이 행사에서는 안과의 주요 의견 리더와 회사 경영진의 발표가 있을 예정이며, 당뇨병성 황반 부종(DME)에서 foselutoclax (UBX1325)와 aflibercept를 비교하는 2b 단계 ASPIRE 연구에 초점을 맞추게 됩니다.
일정에는 세놀리틱 치료 가설, UBX1325의 임상 개발 계획 및 망막 전문가 원탁회의에 대한 논의가 포함됩니다. 24주 안전성 및 유효성 데이터는 2025년 1분기에 발표될 예정이며, 36주 데이터는 2025년 2분기에 발표됩니다. 이 행사는 진화하는 치료 환경과 DME에서의 필요를 충족시키기 위한 UBX1325의 잠재력을 다룰 것입니다. 가상 참가자는 UNITY 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 90일 동안 다시보기 옵션이 제공됩니다.
UNITY Biotechnology (NASDAQ: UBX) a annoncé un événement en présentiel et virtuel dédié à la Journée de l'Ophalmologie pour les investisseurs et les analystes le 15 octobre 2024 à New York. L'événement comportera des présentations d'experts en ophtalmologie et de la direction de l'entreprise, se concentrant sur l'étude ASPIRE de phase 2b de UNITY qui évalue foselutoclax (UBX1325) par rapport à l'aflibercept dans le cadre de l'œdème maculaire diabétique (DME).
L'agenda comprend des discussions sur l'hypothèse thérapeutique sénolytique, le plan de développement clinique de UBX1325, et une table ronde d'experts en rétine. Les données de sécurité et d'efficacité à vingt-quatre semaines sont attendues au premier trimestre 2025, avec des données à trente-six semaines au deuxième trimestre 2025. L'événement abordera le paysage thérapeutique en évolution et le potentiel de UBX1325 pour répondre à des besoins non satisfaits dans le DME. Les participants virtuels peuvent accéder au webcast via le site web de UNITY, avec des rediffusions disponibles pendant 90 jours.
UNITY Biotechnology (NASDAQ: UBX) hat ein persönliches und virtuelles Event zum Tag der Augenheilkunde für Investoren und Analysten am 15. Oktober 2024 in New York angekündigt. Die Veranstaltung wird Präsentationen von führenden Meinungsbildnern auf dem Gebiet der Augenheilkunde sowie von der Unternehmensleitung beinhalten, die sich auf die Phase 2b ASPIRE-Studie von UNITY konzentriert, die foselutoclax (UBX1325) gegen Aflibercept bei diabetischem Makulaödem (DME) untersucht.
Die Agenda umfasst Diskussionen zur senolytischen Therapie-Hypothese, dem klinischen Entwicklungsplan von UBX1325 und einem Experten-Roundtable zur Netzhaut. Sicherheits- und Wirksamkeitsdaten nach vierundzwanzig Wochen werden im ersten Quartal 2025 erwartet, mit Daten nach sechsunddreißig Wochen im zweiten Quartal 2025. Die Veranstaltung wird die sich entwickelnde therapeutische Landschaft und das Potenzial von UBX1325 zur Deckung unerfüllter Bedürfnisse im DME ansprechen. Virtuelle Teilnehmer können über die Website von UNITY auf die Webcast zugreifen, und Wiederholungen werden für 90 Tage zur Verfügung stehen.
- None.
- None.
SAN FRANCISCO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that it will host an in-person and virtual event for investors and analysts on Tuesday, October 15, 2024, at 8:00 a.m. ET in New York, NY. The event will feature presentations from prominent ophthalmology key opinion leaders (KOLs) and company management.
UNITY Biotechnology Ophthalmology Day Agenda
Date: Tuesday, October 15, 2024
Time: 8:00 a.m. until 9:30 a.m. ET
Location: Park Terrace Hotel, New York, NY (with simultaneous webcast)
Registration and Webcast Link: https://lifescievents.com/event/unitybiotechnology/
- Welcome and Introductions: Anirvan Ghosh, Ph.D., Chief Executive Officer, UNITY Biotechnology
- Senolytic Therapeutic Hypothesis: Mike Sapieha, Ph.D., Chief Scientist, UNITY Biotechnology
- UBX1325 Clinical Development Plan – BEHOLD and ASPIRE studies in DME: Robert Bhisitkul, M.D., Ph.D., UCSF School of Medicine
- Retina Expert Roundtable:
- Arshad Khanani, M.D., MA, FASRS, Sierra Eye Associates, University of Nevada Reno School of Medicine
- Dante Pieramici, M.D., California Retina Consultants
- Alicia Tozier, Chief Strategy Officer, UNITY Biotechnology
- Live Q&A
The event will focus on UNITY’s ongoing Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) head-to-head against aflibercept in diabetic macular edema (DME). Twenty-four-week safety and efficacy data are expected in the first quarter of 2025, and 36-week data are expected in the second quarter of 2025. Retina experts will address the evolving therapeutic landscape and the potential of UBX1325 to address unmet needs in DME.
For virtual attendees, the live webcasts of the presentations will be accessible through the “Investors & Media” section of the company’s website, www.unitybiotechnology.com, under “Events & Presentations.” Archived replays will be available for 90 days.
Featured Retina Experts
Robert Bhisitkul, M.D., Ph.D.
Robert Bhisitkul, M.D., Ph.D., is an ophthalmologist and retina specialist at UCSF Health who provides medical and laser treatments for macular degeneration, diabetic retinopathy and other retinal diseases. He also performs macular hole and macular pucker surgeries (conditions that cause blurred or distorted vision), retinal detachment and complications of diabetic eye disease. Dr. Bhisitkul recruits patients to participate in UCSF clinical trials of novel therapies for macular degeneration and diabetic retinopathy, and also for studies on long-term outcomes for treatments such as surgically implantable devices that deliver medication. He has published more than 60 papers in clinical and scientific journals.
Arshad M. Khanani, M.D., MA, FASRS
Arshad M. Khanani, M.D., MA, FASRS, is a Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Associate Professor at the University of Nevada, Reno School of Medicine.
Dr. Khanani founded the clinical research department at Sierra Eye Associates, which is now one of the leading clinical research centers in the country. He has served as a principal investigator for over 100 clinical trials and has been a top enroller in the country for multiple Phase 1-3 trials. In addition, Dr. Khanani was the first to perform surgical procedures in multiple surgical clinical trials dealing with sustained delivery and gene therapy. He has published over 75 scientific publications and is a frequent guest speaker at national and international meetings.
Dante Pieramici, M.D.
Dante Pieramici, M.D. is currently a managing partner of the California Retina Consultants and a member of the Medical Leadership Board of the Retina Consultants of America.
As the Medical Director of Clinical Research at California Retina Consultants, Dr. Pieramici has served as the principal or sub investigator, reading center investigator or advisor for over 100 clinical trials. His research has focused primarily on new surgical and pharmacologic treatments for age-related macular degeneration and diabetic related eye diseases. He has served as a consultant for numerous biotech companies, helping to design, monitor and evaluate clinical trial results for retinal diseases. He has authored over 150 peer-reviewed research papers and book chapters on retinal diseases and has served as editor for the text, Ocular Trauma: Principles and Practice.
Dr. Pieramici currently serves as President of the California Retina Research Foundation and serves as a long-time board member at S.E.E International.
About UBX1325
UBX1325 is an investigational compound being studied in retinal diseases, including DME, and is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of BCL-xL, a member of the BCL-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. The Phase 2 BEHOLD study in patients with DME demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean BCVA through 48 weeks compared to sham treatment. In preclinical studies, UNITY has demonstrated that targeting BCL-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with retinal disease.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Media Contact
Inizio Evoke Comms
Katherine Smith
Katherine.Smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
Source: Unity Biotechnology, Inc.
FAQ
When is UNITY Biotechnology (UBX) hosting its Ophthalmology Day event?
What is the focus of UNITY Biotechnology's (UBX) ASPIRE study?
When are the results of UNITY Biotechnology's (UBX) ASPIRE study expected?
Who are the featured retina experts at UNITY Biotechnology's (UBX) Ophthalmology Day?
How can investors attend UNITY Biotechnology's (UBX) Ophthalmology Day virtually?
